The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

Trial Profile

The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Conbercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Registrational; Therapeutic Use
  • Acronyms SHINY
  • Sponsors Chengdu Kanghong Biological Science & Technology
  • Most Recent Events

    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top